Skip to main content
. Author manuscript; available in PMC: 2022 May 20.
Published in final edited form as: Mol Cell. 2021 Apr 19;81(10):2094–2111.e9. doi: 10.1016/j.molcel.2021.03.043

Figure 1: ZAP70 is aberrantly expressed in a broad range of B-cell malignancies.

Figure 1:

(a) Normalized mRNA expression of SYK and ZAP70 in normal hematopoietic populations. Complemented by Table S1. (b) Normalized mRNA expression of SYK and ZAP70 in B-cell malignancies from patients with: B-ALL (n=637), B-CLL (n=646), MCL (n=174), BL (n=120), DLBCL (n=392) and MM (n=113). Normal B- and T-cells are included as a reference. Dashed line indicates mean ZAP70 expression across B-cell populations. (c) SYK and ZAP70 protein levels were analyzed by Western blotting. Normal CD19+ B-cells and CD3+ T-cells were included as controls. (d-f) Single-cell (sc) protein analyses for SYK and ZAP70. Complemented by Table S2. Sc-WB analysis was performed on (d) normal peripheral blood pan-B (CD19+) and T-cells (CD3+), (e) purified leukemic populations from two different PDX samples of patients with BCR-ABL1 B-ALL, TCF3-PBX1 B-ALL, MCL, DLBCL and 2 primary B-CLL patient samples with unmutated or mutated BCRs, (f) Pro/Pre-B, Immature, and plasma cells purified from BM; CD5+ CD19+, new emigrant mature naïve, and memory B-cells purified from peripheral blood and germinal center B-cells purified from resected tonsillar tissue by flow sorting.